• 1
    Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997; 15: 230238.
  • 2
    Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994; 74: 670678.
  • 3
    Zagars G, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997; 44: 213221.
  • 4
    Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JMG. Overall survival after prostate-specific-antigen detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000; 48: 629633.
  • 5
    Hanks GE, D'Amico A, Epstein BE, Schultheiss TE. Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys. 1993; 27: 125127.
  • 6
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 15911577.
  • 7
    American Joint Committee on Cancer. Prostate. In: FlemingID, CooperJS, HensonDE, et al., editors. AJCC cancer staging manual. Philadelphia: JB Lippincott, 1997: 219224.
  • 8
    Pinover WH, Hanlon A, Lee WR, Kaplan EJ, Hanks GE. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. Cancer. 1996; 77: 13341341.
  • 9
    Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001; 92: 12811287.
  • 10
    International Commission on Radiation Units and Measurements. ICRU report 50: prescribing, recording, and reporting photon beam therapy. Bethesda: International Commission on Radiation Units and Measurements, 1993.
  • 11
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 10351041.
  • 12
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 13
    Wilcoxon F. Individual comparison by ranking methods. Biometrics. 1945; 1: 8083.
  • 14
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 15
    D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 1993; 72: 26382643.
  • 16
    Shipley WU, Lu JD, Pilepich MV, et al. Does neoadjuvant hormone treatment compromise subsequent androgen suppression in prostate cancer patients who fail initial radiation therapy: a secondary analysis of RTOG 86-10. Int J Radiat Oncol Biol Phys. 2000; 48: 169.